- Home
- VRCA vs CUE Comparison
VRCA vs CUE Comparison
Compare VRCA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- CUE
- Stock Information
- Founded
- VRCA 2013
- CUE 2014
- Country
- VRCA United States
- CUE United States
- Employees
- VRCA 71
- CUE N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- CUE Health Care
- Exchange
- VRCA Nasdaq
- CUE Nasdaq
- Market Cap
- VRCA 43.0M
- CUE 58.9M
- IPO Year
- VRCA 2018
- CUE 2018
- Fundamental
- Price
- VRCA $0.49
- CUE $0.79
- Analyst Decision
- VRCA Hold
- CUE Strong Buy
- Analyst Count
- VRCA 5
- CUE 3
- Target Price
- VRCA $6.00
- CUE $3.00
- AVG Volume (30 Days)
- VRCA 431.6K
- CUE 232.9K
- Earning Date
- VRCA 05-12-2025
- CUE 05-08-2025
- Dividend Yield
- VRCA N/A
- CUE N/A
- EPS Growth
- VRCA N/A
- CUE N/A
- EPS
- VRCA N/A
- CUE N/A
- Revenue
- VRCA $7,566,000.00
- CUE $9,287,000.00
- Revenue This Year
- VRCA $127.58
- CUE N/A
- Revenue Next Year
- VRCA $88.06
- CUE $4.77
- P/E Ratio
- VRCA N/A
- CUE N/A
- Revenue Growth
- VRCA 47.66
- CUE 69.16
- 52 Week Low
- VRCA $0.38
- CUE $0.45
- 52 Week High
- VRCA $11.41
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- VRCA 47.66
- CUE 43.53
- Support Level
- VRCA $0.45
- CUE $0.74
- Resistance Level
- VRCA $0.59
- CUE $0.86
- Average True Range (ATR)
- VRCA 0.08
- CUE 0.09
- MACD
- VRCA 0.00
- CUE 0.02
- Stochastic Oscillator
- VRCA 26.74
- CUE 66.14
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.